Pharmala Biotech Holdings (XCNQ:MDMA) Dividends per Share : C$0.00 (TTM As of Feb. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Dividends per Share?

Pharmala Biotech Holdings's dividends per share for the three months ended in Feb. 2025 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Feb. 2025 was C$0.00. Its Dividend Payout Ratio for the three months ended in Feb. 2025 was 0.00. As of today, Pharmala Biotech Holdings's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Pharmala Biotech Holdings Dividends per Share Historical Data

The historical data trend for Pharmala Biotech Holdings's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Dividends per Share Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Dividends per Share

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
Dividends per Share	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Pharmala Biotech Holdings's Dividends per Share

For the Biotechnology subindustry, Pharmala Biotech Holdings's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Pharmala Biotech Holdings Dividends per Share Calculation

Dividends paid to per common share.

Pharmala Biotech Holdings (XCNQ:MDMA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Pharmala Biotech Holdings's Dividend Payout Ratio for the quarter that ended in Feb. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2025 )	/	EPS without NRI (Q: Feb. 2025 )
	=	0	/	-0.01
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Pharmala Biotech Holdings Dividends per Share Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

MDXXF:USA

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.

Executives

Fraser Macdonald	Director
Perry Tsergas	Director
Shane H.d. Morris	Director, Senior Officer
Nicholas Kadysh	Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines